AnaptysBio - Home
About
Overview
Strategy
Management
Board of Directors
Research and Development Committee
Contact
Technology
Therapeutic Antibodies
Somatic Hypermutation
SHM Platform
Key Advantages
Publications
Pipeline
Overview
Imsidolimab
ANB030
ANB032
Partnerships
Investors / News
Overview
News
Events
Goverance
Stock Information
Analyst Coverage
SEC Filings
FAQs
Contact
Careers
Overview
Job Openings
Health and Financial Benefits Overview
Toggle
Therapeutic Antibodies
for Severe Disease
Therapeutic Antibodies
for Severe Disease
Therapeutic Antibodies
for Severe Disease
February 25, 2021
AnaptysBio Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Pipeline Updates
AnaptysBio Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Pipeline Updates
January 16, 2021
GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solid cancers at ASCO Gastrointestinal Cancers Symposium — Data from GARNET cohort F shows a 38.7% objective response rate with dostarlimab in patients with dMMR advanced solid cancers
GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solid cancers at ASCO Gastrointestinal Cancers Symposium — Data from GARNET cohort F shows a 38.7% objective response rate with dostarlimab in patients with dMMR advanced solid cancers
About
Technology
Pipeline
Investors
Careers
